The board of immunology biotech Acelyrin has rejected the buyout offer from Tang Capital’s shell company Concentra Biosciences, clearing up any doubt about its pending merger with Alumis. After consulting with outside financial and legal advisors, Acelyrin said its board found the unsolicited interest from Concentra “is not reasonably expected to result in a superior proposal to the planned merger with Alumis.”
Read the full article: Acelyrin Rejects Buyout Offer from Tang’s Concentra, Sticks to Alumis Merger //
Source: https://endpts.com/acelyrin-rejects-buyout-offer-from-tangs-concentra-sticks-to-alumis-merger